用于细旦长丝变形的MPS CoolFlex

由于能耗可降低30%,MPS变形机可很容易地将速度提高30%,从而使MPS的构想成为一种用于细旦长丝变形加工的十分经济的方案.     

用MPS变形机生产花式长丝

描述了德国巴马格公司的MPS变形机的特性和应用.MPS变形机的理念使长丝生产商对于市场的需求能作出迅速有效的响应.已生产的长丝大致可分为三类:与通常变形丝手感不同的长丝、与标准变形丝染色特性不同的长丝及在某种程度上同时显示以上两种特性的长丝.     

用MPS变形机加工新型聚合物

描述了德国巴马格公司生产的MPS变形机的特点和应用.MPS变形机加工的一些新型聚合物--PTT和PLA,用可再生原料制造,也是可生物降解的.比较了PTT、PLA和各种常用纤维的性质.     

合纤变形--未来变形丝发展新思路

本文分析了合纤变形工艺的发展及其影响因素，介绍了假捻变形、空气喷射变形和BCF变形技术，并介绍了Rieter公司变形机的发展过程及其优良的性能。     

粗旦花式变形丝的开发

对粗旦花式变形丝的变形原理、变形机的使用、变形工艺参数进行了论述。对原丝在变形过程中各个工艺参数进行了较为详细的分析。     

世界拉伸变形机市场趋势

自1994年以来,国际纺织制造商联盟(ITMF,瑞士苏黎世)就已将假捻拉伸变形机(不包括聚酰胺、PET、聚丙烯及膨化变形长丝地毯纱和喷气变形机)纳入年度纺织机械(纺纱机、织机和针织机)调查中了.自1994年以来,变形纱生产商(纤维生产商和捻丝厂商)投资了134 000个聚酰胺变形丝锭和1 970 000个PET变形丝锭子.     

Menegatto公司的TMA型纤维变形机

在米兰召开的1995年国际纺织机械博览会上,出现了一家新的变形机生产商,意大利的Menegatto公司。该公司以生产弹性纤维用包纱机而闻名。在这次博览会上,该公司展出了一种高速(最高达1500m/min)的带有一短小加热器的纤维变形机,型号为TMA。该机器有FT和FTF两类,每个纺丝位都有手动或自动卷绕选择。     

SSM喜获新订单

日前,瑞士纺织机械制造商SSM公司在其举办的新闻发布会上发出消息,SSM从世界知名高品质锦纶丝生厂商手中获得了一个23台设备的大订单。SSM公司将提供总共20台TG.30A全自动假捻变形机,1台TG3.0 AE集成弹性展开装置的自动假捻变形机,1台适用于粗纱支的RG．12DTB自动假捻变形机和1台DP5-T的FastFlex空气变形机。     

FK6-700型拉伸变形机电气改造及计算机群控系统

介绍一种低造价高性能的FK6-700型拉伸变形机计算机控制与管理系统,对FK-700型拉伸变形机的电气系统进行改造,系统采用工业PC机、PLC、变频器等组成一种模块化的体系结构.     

拉伸变形机全球市场趋势

瑞士苏黎世国际纺织品制造商联盟（ITMF）从1994年开始,就已将全球假捻变形机（不包括PA、PET、PPBCF地毯纱及喷气变形机）的规模囊括在其每年纺织机械（纺纱机、织机、大圆机、横机以及纺织后整理设备）的调研中。     

Separation and characteristics of different mucopolysaccharides from bovine trachea cartilage

Bovine trachea cartilage may be used as a source of mucopolysaccharides (MPS) for medical and cosmetic purposes. The content of MPS in bovine cartilage ranged from 10 to 11%, on a dry weight basis. Grade MPS isolation involved hydrolysis of the tissue with papain at 60 °C for 24 h at a tissue to enzyme solution ratio of 1:3 (w/v), separation of enzyme and some peptides with trichloroacetic acid and subsequent precipitation of MPS with ethanol. The MPS contained 54% of polysaccharides and about 27% of residual peptides. The crude MPS were purified and separated into four fractions by precipitation with ethanol at concentrations in reaction media of 20, 30, 40 and 66% (v/v). These fractions contributed 88, 16.5, 1.5 and 8%, respectively, to the hexosamines present in crude MPS. Total MPS recovery in all fractions was 71% of crude MPS weight. The main components of fractions I, II and IV were chondroitin sulphates, hyaluronic acid, and keratosulphates, respectively. However, fraction III contained 1.6% of total MPS of an unidentified polysaccharide.     

Comparison of the effect of multipurpose contact lens solutions on the viability of cultured corneal epithelial cells

Purpose

To determine the effect of four marketed multipurpose contact lens solutions (MPSs) on corneal epithelial cell viability.

Methods

Comparison of the effect of MPS A (Renu MultiPlus, Bausch &; Lomb), MPS B (OPTI-FREE Express, Alcon), MPS C (AQuify, CibaVision), and MPS D (OPTI-FREE RepleniSH, Alcon) on cell viability was performed by quantifying cellular ATP content, resazurin reduction, and lactate dehydrogenase (LDH) release in transformed human corneal epithelial cells (HCEpiC) and primary bovine corneal epithelial cells (BCEpiC).

Results

Significant reductions in cellular ATP content were observed at 40% solution and above with both MPS B and MPS D, compared to at 100% only for MPS A and MPS C, and similar results were obtained in BCEpiC. Effects on resazurin reduction were also less in HCEpiC exposed to increasing doses of MPS A and MPS C than in cells exposed to MPS B and MPS D. After 15 min, HCEpiC viability measured by both resazurin reduction and cellular ATP levels was significantly lower for cells exposed to MPS B, MPS D, and MPS C, while HCEpiC exposed to MPS A were not affected. MPS B and MPS D reduced cell viability more than MPS A and MPS C over a 2-h time course in both HCEpiC and BCEpiC.

Conclusions

Both MPS B and MPS D can cause large decreases in the viability of cultured corneal epithelial cells even with just a 2 h exposure at multiple doses. Significant reduction in cell viability is evident at brief 15-30 min exposures. In contrast, MPS A and MPS C have significantly less effect on the cell viability of corneal epithelial cells at multiple doses, after these short exposure times.     

玛咖多糖的提取条件及体外活性研究

优化玛咖多糖的提取条件,并通过体外实验对其抗氧化活性和降血脂功效进行研究。采用超声波辅助热水浸提并结合响应面法对玛咖多糖提取条件进行优化,通过自由基清除率评价玛咖多糖的抗氧化活性,基于玛咖多糖与胆酸钠的结合能力评价其降血脂功效。在提取温度50℃,提取时间42 min,超声功率220 W,料液比(g/mL)1∶32的条件下,多糖提取率达到最高11.0%。将玛咖粗多糖通过离子交换柱分离得到3个多糖组分,分别为玛咖多糖1、玛咖多糖2和玛咖多糖3。其中玛咖粗多糖、玛咖多糖1和玛咖多糖2具有较强的抗氧化活性,对DPPH自由基的较佳清除率分别为83.9%、81.8%和63.7%,对羟基自由基的较佳清除率分别为73.3%、56.8%和76.7%。此外,玛咖多糖3在体外对牛磺胆酸钠和甘氨胆酸钠的结合率分别为49.1%和32.3%。研究表明,玛咖粗多糖、玛咖多糖1和玛咖多糖2具有较好的抗氧化活性,玛咖多糖3具有一定的降血脂功效。     

Effect of a novel multipurpose contact lens solution on human corneal epithelial barrier function

PurposeTo explore the effect of a novel multipurpose contact lens solution (MPS) on the junction protein distribution and barrier function of cultured human corneal epithelial cell monolayers.MethodsCultured human corneal epithelial cells (HCEpiC) were exposed to a novel MPS (MPS A; Biotrue? multi-purpose solution, Bausch & Lomb Incorporated) at 50%, 75% and 100% for 10 or 30 min. Four commercially available MPS products, MPS B (AQuify, Ciba Vision), MPS C (COMPLETE MPS Easy Rub, AMO), MPS D (OPTI-FREE Express, Alcon) and MPS E (OPTI-FREE RepleniSH, Alcon) were tested in parallel. Tight junction structure and integrity were evaluated by confocal microscopy using ZO-1 antibody and scanning microscopy (SEM). Quantitative evaluation of MPSs on epithelial barrier function was determined by measuring transepithelial electrical resistance (TEER) across HCEpiC grown on Transwell Clear permeable supports and on electric cell-substrate impedance sensing (ECIS) electrode arrays.ResultsOverall after exposure to the three concentrations (50%, 75%, and 100%) of MPS A, ZO-1 distribution and fluorescent intensity on the cell surface appeared similar to the media control with continuous tight junctions and clear intercellular junctions. At all measured time points after exposure to MPS A (50% or 75%) there was also no effect on the TEER using both resistance methodologies, and SEM showed that MPS A appeared similar to the Hank's balanced salt solution (HBSS) control. In cells exposed to MPS D there was a dose-dependent change in the distribution of ZO-1, some cell detachment, and a decrease in monolayer resistance at all time points measured. Ultrastructurally, MPS D caused gross changes, including damage to cell junctions and plasma membranes. To a lesser extent, the remaining three commercial MPS products demonstrated some effects on tight junction ZO-1 distribution and/or TEER.ConclusionsBased on the in vitro measurements of tight junction protein expression, monolayer integrity, and transepithelial electrical resistance, the novel multipurpose contact lens solution (MPS A) did not alter corneal barrier function as compared to media, PBS or HBSS control. Clinical significance of the observed differences in epithelial barrier function among the MPSs tested needs further investigation.     

Whey protein-derived exosomes increase protein synthesis and hypertrophy in C2­C12 myotubes

We sought to examine potential amino acid independent mechanisms whereby hydrolyzed whey protein (WP) affects muscle protein synthesis (MPS) and anabolism in vitro. Specifically, we tested (1) whether 3-h and 6-h treatments of WP, essential amino acids, or l-leucine (Leu) affected MPS, and whether 6-h treatments with low-, medium-, or high doses of WP versus Leu affected MPS; (2) whether knockdown of the primary Leu transporter affected WP- and Leu-mediated changes in MPS, mammalian target of rapamycin (mTOR) signaling responses, or both, following 6-h treatments; (3) whether exosomes isolated from WP (WP-EXO) affected MPS, mTOR signaling responses, or both, compared with untreated (control) myotubes, following 6-h, 12-h, and 24-h treatments, and whether they affected myotube diameter following 24-h and 48-h treatments. For all treatments, 7-d post-differentiated C₂C₁₂ myotubes were examined. In experiment 1, 6-h WP treatments increased MPS compared with control (+46%), Leu (+24%), and essential amino acids (+25%). Moreover, the 6-h low-, medium-, and high WP treatments increased MPS by approximately 40 to 50% more than corresponding Leu treatments. In experiment 2 (LAT short hairpin RNA-transfected myotubes), 6-h WP treatments increased MPS compared with control (+18%) and Leu (+19%). In experiment 3, WP-EXO treatments increased MPS over controls at 12 h (+18%) and 24 h (+45%), and myotube diameters increased with 24-h (+24%) and 48-h (+40%) WP-EXO treatments compared with controls. The WP-EXO treatments did not appear to operate through mTOR signaling; instead, they increased mRNA and protein levels o eukaryotic initiation factor 4A. Bovine-specific microRNA following 24-h WP-EXO treatments were enriched in myotubes (chiefly miR-149-3p, miR-2881), but were not related to hypertrophic gene targets. To summarize, hydrolyzed WP-EXO increased skeletal MPS and anabolism in vitro, and this may be related to an unknown mechanism that increases translation initiation factors rather than enhancing mTOR signaling or the involvement of bovine-specific microRNA.     

Understanding the sensitivity of muscle protein synthesis to dairy protein in middle-aged men

Although the consumption of dairy protein results in a robust increase in muscle protein synthesis (MPS), the magnitude of the increase is dependent upon the dose of protein ingested and the age of the individual. The minimum dose of dairy protein that can stimulate MPS in middle age (50.1 ± 4.5 years), a period of life during which muscle mass is typically lost, is not known. Sixteen middle-aged men (45–60 years) were randomly assigned to consume beverages containing either 10 g of milk protein (MP10) or 6 g of MP plus 20 g of carbohydrate (MP6 + CHO). A primed constant infusion of ¹³C₆ phenylalanine was maintained and muscle biopsy samples were collected to calculate MPS. MP10 increased MPS above fasting levels for 90 min after ingestion, whereas MP6 + CHO did not increase MPS. This study demonstrates that between 6 and 10 g of MP is required to stimulate MPS in middle-aged men.     

In vitro biocompatibility assessment of multipurpose contact lens solutions: effects on human corneal epithelial viability and barrier function

PurposeTo explore the in vitro effects of multipurpose contact lens solutions (MPSs) on corneal epithelial barrier function and viability.MethodsHuman corneal epithelial cells (HCEpiC) were exposed to 50% MPSs A–G. Viability was determined using metabolic activity, protease release and caspase assays. Barrier function was evaluated using immunostaining for the tight junction protein zonnula occludens-1 (ZO-1) and resistance measurements.ResultsMPS A and G did not affect HCEpiC monolayer viability after 2 h, while MPSs B–F significantly decreased viability. There was a significant decrease in stratified HCEpiC viability after exposure to MPSs B–E for 2 h, while there was no effect of MPS A. After exposure of HCEpiC monolayers to MPS A, F or G for 30 min, ZO-1 staining appeared similar to control. HCEpiC exposed to MPSs B and C demonstrated tight junction breakdown. There was no significant change in HCEpiC monolayer resistance after exposure to MPS A or F for 2 h, while MPSs B–E and G reduced resistance. After exposure to MPS A–E, stratified HCEpiC resistance was significantly decreased after 2 or 4 h. The decrease in resistance was significantly less with MPS A as compared to the other MPSs.ConclusionsMPSs caused varying modifications to cell viability and barrier function in monolayer and stratified HCEpiC. MPS A did not alter monolayer HCEpiC viability or barrier function, while MPSs B–G caused significant decreases of at least one parameter. Furthermore, MPS A had significantly less effect than MPSs B–E on viability and barrier function of stratified HCEpiC.     

Fat reduction in emulsion sausage using an enzyme‐modified potato starch

BACKGROUND: A heat‐stable amylase‐modified potato starch (MPS) was prepared and used as a fat replacer in reduced‐fat emulsion sausages. The effects of fat level (50, 150 and 300 g kg^?1) and MPS addition (20 and 40 g kg^?1) on energy, colour, sensory, and textural properties of emulsion sausages were investigated. RESULTS: The addition of 20 or 40 g kg^?1 of MPS in reduced‐fat sausage (50–150 g kg^?1 fat) reduced total energy (15.1–49.4%), increased lightness, but lowered redness of the products (P < 0.05). The 150 g kg^?1 or 50 g kg^?1 fat sausages containing 20 g kg^?1 MPS had a similar hardness to the 300 g kg^?1 fat control (P > 0.05). Sensory evaluation indicated that the presence of MPS in reduced‐fat sausages increased (P < 0.05) the product's tenderness. CONCLUSION: Overall, the 150 g kg^?1 fat emulsion sausages with 20 g kg^?1 MPS were comparable to the 300 g kg^?1 fat control sausage in colour, texture profile, and sensory properties, but was lower in energy, suggesting that the MPS can be used as a potential fat replacer in sausage products. Copyright © 2008 Society of Chemical Industry     

Nonclinical safety evaluation of boric acid and a novel borate-buffered contact lens multi-purpose solution,Biotrue™ multi-purpose solution

Multipurpose solutions (MPS) often contain low concentrations of boric acid as a buffering agent. Limited published literature has suggested that boric acid and borate-buffered MPS may alter the corneal epithelium; an effect attributed to cytotoxicity induced by boric acid. However, this claim has not been substantiated. We investigated the effect of treating cells with relevant concentrations of boric acid using two cytotoxicity assays, and also assessed the impact of boric acid on corneal epithelial barrier function by measuring TEER and immunostaining for tight junction protein ZO-1 in human corneal epithelial cells. Boric acid was also assessed in an in vivo ocular model when administered for 28 days. Additionally, we evaluated Biotrue multi-purpose solution, a novel borate-buffered MPS, alone and with contact lenses for ocular compatibility in vitro and in vivo. Boric acid passed both cytotoxicity assays and did not alter ZO-1 distribution or corneal TEER. Furthermore, boric acid was well-tolerated on-eye following repeated administration in a rabbit model. Finally, Biotrue multi-purpose solution demonstrated good ocular biocompatibility both in vitro and in vivo. This MPS was not cytotoxic and was compatible with the eye when administered alone and when evaluated with contact lenses. We demonstrate that boric acid and a borate-buffered MPS is compatible with the ocular environment. Our findings provide evidence that ocular effects reported for some borate-buffered MPS may be incorrectly attributed to boric acid and are more likely a function of the unique combination of ingredients in the MPS formulation tested.